<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151539</url>
  </required_header>
  <id_info>
    <org_study_id>VICC BMT 1401</org_study_id>
    <secondary_id>NCI-2014-01026</secondary_id>
    <secondary_id>VICC BMT 1401</secondary_id>
    <secondary_id>P30CA068485</secondary_id>
    <nct_id>NCT02151539</nct_id>
  </id_info>
  <brief_title>Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)</brief_title>
  <acronym>POSTAGE</acronym>
  <official_title>Prospective Outcomes of Second-Line Therapy in Acute Graft-Versus-Host Study Including ECP (POSTAGE)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research trial studies medical chart review in determining outcomes of second-line
      therapy in patients with acute graft-versus-host disease previously treated with
      extracorporeal photopheresis or other systemic therapies. Gathering information about
      second-line therapy in patients with acute graft-versus-host disease may help doctors learn
      more about the disease and find better treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine 6-month freedom from treatment failure for second-line therapy for acute
      graft versus host disease (aGVHD).

      II. To show that extracorporeal photopheresis (ECP) is associated with a superior 6 month (m)
      freedom from treatment failure (FFTF) as compared to other treatment modalities for second
      line therapy for aGVHD.

      III. To describe health care burden in patients receiving second line therapy for acute GVHD.

      IV. Quality of life measurement using Functional Assessment of Cancer Therapy-Bone Marrow
      Transplant (FACT-BMT) in patients receiving second line therapy for aGVHD.

      OUTLINE:

      Study data are collected and managed using Research Electronic Data Capture (REDCap) tools at
      baseline and on days 5, 28, and 56.

      After completion of study, patients are followed up at 6 months, and 1 and 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>6-month freedom from treatment failure, defined as a patient being alive, without relapse of underlying disease, and without the addition of new systemic therapy for the treatment of aGVHD, within 6 months of starting second line therapy</measure>
    <time_frame>6 months</time_frame>
    <description>Rates of 6 m FFTF will be estimated by subtracting rates of total failures from 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence estimates of relapse</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Cox regression models will be used to identify risk factors for failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence estimates of non-relapse mortality</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Cox regression models will be used to identify risk factors for failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment change as causes of failure during second line treatment</measure>
    <time_frame>Up to 2 years</time_frame>
    <description>Cox regression models will be used to identify risk factors for failure.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health care burden in patients receiving second line therapy for acute GVHD</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>The incremental budget spend between the patients receiving treatment with ECP and patients receiving other modalities will be measured and economic methods will be used to calculate an incremental cost effectiveness ratio for relevant clinical end points. Health economic data relating to hospitalizations (length of stay in myelosuppressive unit, high-dependency unit [step-down unit], intensive care unit), high cost drugs, total parenteral nutrition and surgical procedures will also be collected allowing comparisons to be made between patients treated with ECP and other treatment options.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life measured using FACT-BMT</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">105</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>Observational (medical chart review)</arm_group_label>
    <description>Study data are collected and managed using REDCap tools at baseline and on days 5, 28, and 56.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>medical chart review</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (medical chart review)</arm_group_label>
    <other_name>chart review</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality-of-life assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Observational (medical chart review)</arm_group_label>
    <other_name>quality of life assessment</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        This study targets patients with acute graft-versus-host disease previously treated with
        extracorporeal photopheresis or other systemic therapies. Patients can be enrolled by all
        participating locations.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrollment on study is within 5 days (including weekends) of starting second-line
             therapy

          -  aGVHD grade 2 or higher at time of enrollment; patients with late acute and recurrent
             aGVHD are permitted

          -  Donor lymphocyte induced aGVHD is permitted ONLY IF donor lymphocyte infusion given
             for mixed chimerism and not for progression of disease and meeting all other inclusion
             and exclusion criteria will be eligible

          -  Corticosteroid refractory or corticosteroid dependent aGVHD

               -  Corticosteroid refractory aGVHD is defined as worsening of aGVHD after 3 days of
                  systemic corticosteroids (minimum dose of 1 mg/kg), or no improvement after 7
                  days of systemic corticosteroids (minimum dose of 1 mg/kg)

               -  Corticosteroid dependent aGVHD is defined as recurrence of aGVHD (grade 2 or
                  higher) during corticosteroid taper and prior to reaching 50% of initial starting
                  dose of corticosteroids

          -  Informed consent form

        Exclusion Criteria:

          -  Has received corticosteroids at 2 mg/kg or higher for 3 weeks or longer as part of
             first-line therapy for aGVHD

          -  Has received systemic therapy other than corticosteroids for treatment of aGVHD as
             part of first-line therapy for acute GVHD; simultaneous uses of topical or enteric
             corticosteroids or psoralen plus ultraviolet A (PUVA) for first-line are permitted

          -  aGVHD after second hematopoietic cell transplantation (HCT) is excluded

          -  Karnofsky performance status =&lt; 50%

          -  Requiring mechanical ventilation or renal replacement therapy at the time of
             enrollment

          -  Histologic or flow-cytometric evidence of relapse or progression of underlying
             disease; molecular or cytogenetic presence of disease is permitted; mixed chimerism is
             permitted

          -  Current or prior diagnosis of chronic GVHD (classic or overlap) as defined by National
             Institutes of Health (NIH) consensus criteria

          -  Donor lymphocyte infusion (DLI)-induced aGVHD when DLI was given for progression of
             the underlying disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Madan Jagasia</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt-Ingram Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanderbilt Cancer Center Clinical Trial Information Program</last_name>
    <phone>800-811-8480</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Mayo Clinic in Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office (toll free)</last_name>
      <phone>855-776-0015</phone>
    </contact>
    <investigator>
      <last_name>Nandita Khera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital - Westwood Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center (VICC)</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VICC Clinical Trials Office</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Madan H. Jagasia</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>A-1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hildegard Greinix</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universit√§t Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Daniel Wolff</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Emma Das-Gupta</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.vicc.org/ct/</url>
    <description>Vanderbilt-Ingram Cancer Center, Find a Clinical Trial</description>
  </link>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <last_update_submitted>August 11, 2017</last_update_submitted>
  <last_update_submitted_qc>August 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 15, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Madan Jagasia, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

